Phosphatidylinositide-3 kinase: A newer molecular target in metabolic and hormonal pathway of polycystic ovary syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 5, 2014, Pages 261-267

  Shah, K N ^a   Patel, S S ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

hyperandrogenemia; insulin resistance; phosphatidylinositol 3 kinase; polycystic ovary syndrome (PCOS)

Indexed keywords

ANDROGEN; AROMATASE; AUTOANTIBODY; CYTOCHROME P450 17; CYTOCHROME P450 17A1; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PLECKSTRIN; PROGESTERONE; PROTEIN KINASE B; PROTEIN P53; TESTOSTERONE; UNCLASSIFIED DRUG; GLUCOSE;

ADIPOCYTE; ADIPOSE TISSUE; ANDROGEN SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GRANULOSA CELL; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEROIDOGENESIS; THECA CELL; ANIMAL; DRUG DELIVERY SYSTEM; FEMALE; METABOLISM; MORTALITY; POLYCYSTIC OVARY SYNDROME;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; GLUCOSE; HUMANS; INSULIN; PHOSPHATIDYLINOSITOL 3-KINASES; POLYCYSTIC OVARY SYNDROME;

EID: 84901238676     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1372578     Document Type: Review

References (64)

1. Baillargeon J. P., Iuorno M. J., Nestler J. E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol: 2003; 46 325 340 (Pubitemid 36859374)
2. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med: 2010; 8 41 51
3. Gordon J. D., Rydfors J., Druzin M. et al. Reproductive endocrinology. In: Gordon J. D. (ed.) Obstetrics, Gynecology and Infertility, Handbook for clinicians. Virginia ScrubHill Press: 2007; 492 506
4. The Rotterdam ESHRE ASRM-sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril: 2004; 81 19 25
5. Diamanti-Kandarakis E., Kandarakis H., Legro R. S. The role of genes and environment in the etiology of PCOS. Endocrine: 2006; 30 19 26 (Pubitemid 46020326)
6. Strauss J. F. 3rd. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann N Y Acad Sci: 2003; 997 42 48
7. Amato P., Simpson J. L. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol: 2004; 18 707 718 (Pubitemid 40424606)
8. O'Meara N. M., Blackman J. D., Ehrmann D. A. et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab: 1993; 76 1241 1247 (Pubitemid 23155443)
9. Dunaif A., Xia J., Book C. B. et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest: 1995; 96 801 810
10. Poretsky L., Smith D., Seibel M. et al. Specific insulin binding sites in human ovary. J Clin Endocrinol Metab: 1984; 59 809 811 (Pubitemid 14012513)
11. Virkamäki A., Ueki K., Kahn C. R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest: 1999; 103 931 943 (Pubitemid 29169600)
12. Cheatham B., Kahn C. R. Insulin action and the insulin signaling network. Endocr Rev: 1995; 16 117 142
13. Cantrell D. A. Phosphoinositide 3-kinase signalling pathways. J Cell Sci: 2001; 114 1439 1445 (Pubitemid 32427831)
14. Lawrence JC J., Roach P. J. New insight into the role and mechanism of glycogen synthase activation by insulin. Diabetes: 1997; 46 541 547 (Pubitemid 27143368)
15. Saltiel A. R. Diverse signaling pathways in the cellular actions of insulin. Am J Physiol: 1996; 270 E375 E385
16. White M. F., Yenush L. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol: 1998; 228 179 208
17. Vanhaesebroeck B., Leevers S. J., Ahmadi K. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem: 2001; 70 535 602 (Pubitemid 32662219)
18. Cantley L. C. The phosphoinositide 3-kinase pathway. Science: 2002; 296 1655 1657 (Pubitemid 34579158)
19. Stephens L. R., Eguinoa A., Erdjument-Bromage H. et al. The Gbc sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell: 1997; 89 105 114 (Pubitemid 27180590)
20. Dowler S., Currie R. A., Campbell D. G. et al. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide- binding specificities. Biochem J: 2000; 351 19 27
21. Rohrschneider L. R., Fuller J. F., Wolf I. et al. Structure, function and biology of SHIP proteins. Genes Dev: 2000; 14 505 520 (Pubitemid 30159771)
22. Wishart M. J., Dixon J. E. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol: 2002; 12 579 585 (Pubitemid 35461856)
23. Dunaif A., Segal K. R., Shelley D. R. et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes: 1992; 41 1257 1266
24. Ciaraldi T. P., El-Roeiy A., Madar Z. et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab: 1992; 75 577 583
25. Ciaraldi T. P., Morales A. J., Hickman M. G. et al. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab: 1997; 82 1421 1425 (Pubitemid 27200412)
26. Lystedt E., Westergren H., Brynhildsen J. et al. Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness. Eur J Endocrinol: 2005; 153 831 835 (Pubitemid 43020233)
27. Rosenbaum D., Haber R., Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT4 glucose transporters in adipocytes. Am J Physiol: 2003; 264 E197 E202
28. Diamanti-Kandarakis E., Papavasiliou A. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med: 2006; 12 324 332 (Pubitemid 44094292)
29. Goodarzi M. O., Antoine H. J., Pall M. et al. Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of the polycystic ovary syndrome. Fertil Steril: 2007; 87 1473 1476 (Pubitemid 46829128)
30. Cortón M., Botella-Carretero J. I., Bengura A. et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2007; 92 328 337 (Pubitemid 46075011)
31. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev: 1997; 18 774 800 (Pubitemid 28009567)
32. Taylor S. I., Cama A., Accili D. et al. Mutations in the Insulin Receptor Gene. Endocr Rev: 1992; 13 566 595
33. Hotamisligil G. S., Peraldi P., Budavari A. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science: 1996; 271 665 668 (Pubitemid 26052915)
34. Maddux B. A., Sbraccia P., Kumakura S. et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature: 1995; 373 448 451
35. Griffin M. E., Marcucci M. J., Cline G. W. et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes: 1999; 48 1270 1274 (Pubitemid 29241025)
36. Book C. B., Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab: 1999; 84 3110 3116 (Pubitemid 30646930)
37. DeFronzo R. A., Jacot E., Jequier E. et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes: 1981; 30 1000 1007
38. Corbould A., Kim Y. B., Youngren J. F. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab: 2005; 288 E1047 E1054 (Pubitemid 40547900)
39. Holman A., Svedberg J., Jennische E. et al. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol: 1990; 259 E555 E560 (Pubitemid 20340374)
40. Manneras L., Cajander S., Holman A. et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology: 2007; 148 3781 3791 (Pubitemid 47105840)
41. Dunaif A., Wu X., Lee A. et al. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab: 2001; 281 E392 E399
42. Nestler J. E., Jakubowicz D. J., de Vargas A. F. et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab: 1998; 83 2001 2005 (Pubitemid 28496328)
43. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab: 1995; 80 3788 3790
44. Cara J. R., Rosenfield R. L. Insulin-like growth factor I and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal interstitial cells. Endocrinology: 1988; 123 733 739
45. Buyalos R. P. Insulin-like growth factor binding proteins in disorders of androgen excess. Sem Reprod Endocrinol: 1994; 12 21 25 (Pubitemid 24122083)
46. Romero G., Garmey J. C., Veldhuis J. D. The involvement of inositol phosphoglycan mediators in the modulation of steroidogenesis by insulin and insulin-like growth factor-I. Endocrinology: 1993; 132 1561 1568 (Pubitemid 23110525)
47. Nestler J. E. Role of obesity and insulin in the development of anovulation. In: Filicori M., Flamigni C. (ed.) Ovulation Induction: Basic Science and Clinical Advances. Amsterdam Elsevier: 1994; 103 114
48. Unger J. W., Livingston J. N., Moss A. M. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol: 1991; 36 343 362
49. Burger C. W., Korsen T., Van Kessel H. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. J Clin Endocrinol Metab: 1985; 61 1126 1132 (Pubitemid 16186713)
50. Diamanti-Kandarakis E., Papavassiliou A. G. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med: 2006; 12 324 332 (Pubitemid 44094292)
51. Munir I., Yen H., Geller D. H. et al. Insulin augmentation of 17a-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology: 2004; 145 175 183 (Pubitemid 38094513)
52. Nelson-Degrave V. L., Wickenheisser J. K., Hendricks K. L. et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol: 2005; 19 379 390 (Pubitemid 40223462)
53. Poretsky L., Seto-Young D., Shrestha A. et al. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab: 2001; 86 3115 3119 (Pubitemid 32673474)
54. Seto-Young D., Zajac J., Liu H. C. et al. The role of mitogen-activated protein kinase in insulin and insulin-like growth factor I (IGF-I) signaling cascades for progesterone and IGF-binding protein-1 production in human granulosa cells. J Clin Endocrinol Metab: 2003; 88 3385 3391 (Pubitemid 36877521)
55. Flores J. A., Garmey J. C., Nestler J. E. et al. Sites of inhibition of steroidogenesis by activation of protein kinase-C in swine ovarian (granulosa) cells. Endocrinology: 1993; 132 1983 1990 (Pubitemid 23133244)
56. Greisen S., Ledet T., Ovesen P. Effects of androstenedione, insulin and luteinizing hormone on steroidogenesis in human granulosa luteal cells. Hum Reprod: 2001; 16 2061 2065 (Pubitemid 32951895)
57. Sekar N., Lavoie H. A., Veldhuis J. D. Concerted regulation of steroidogenic acute regulatory gene expression by luteinizing hormone and insulin (or insulin-like growth factor I in primary cultures of porcine granulosa luteal cells. Endocrinology: 2000; 141 3983 3992
58. Erickson G. F., Magoffin D. A., Cragun J. R. et al. The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab: 1990; 70 894 902
59. Bals-Pratsch M., Grober B., Seifert B. et al. Early Onset and High Prevalence of Gestational Diabetes in PCOS and Insulin Resistant Women Before and After Assisted Reproduction. Exp Clin Endocrinol Diabetes: 2011; 119 338 342
60. Moeini A., Mansoori M., Eslami B. et al. Evaluating Endometrial Hyperplasia in Infertile Women with Polycystic Ovarian Syndrome in Roointan-Arash Hospital. J Reprod Infertil: 2008; 8 330 336
61. Temple K. A., Watson S., Whitmore H. et al. Obstructive Sleep Apnea in Women with Polycystic Ovary Syndrome Increases the Risk of Abnormal Glucose Tolerance. Endocr Rev: 2012; 33 47 54
62. Hachmi BS L., Hachmi BS S., Bouzid C. et al. Hypertension in polycystic ovary syndrome. Arch Mal Coeur Vaiss: 2006; 99 687 690
63. Carmina E., Lobo R. A. Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. J Clin Endocrinol Metab: 1999; 84 1897 1899 (Pubitemid 30647006)
64. Wang J. X., Davies M. J., Norman R. J. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod: 2001; 16 (Pubitemid 34007478)